Endologix Inc (ELGX):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Endologix Inc (ELGX) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7516
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Endologix, Inc. (Endologix) is a medical device company. It undertakes the development, manufacturing and selling of minimally invasive treatments for aortic diseases. The company lays focus on its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). The company’s AAA products are built on traditional minimally-invasive endovascular repair (EVAR) platform or endovascular sealing (EVAS) platform. The company’s EVAR products include AFX endovascular AAA system Vela Proximal Endograft and Intuitrak endovascular AAA system; and EVAS products comprise Nellix endovascular aneurysm sealing system. It has manufacturing facility in Irvine. The company sells its products to hospitals in the US and Europe through direct sales force and through third-party international distributors and agents in other parts of the world. Endologix is headquartered in California, the US.

Endologix Inc (ELGX) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Endologix Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Endologix Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Endologix Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Endologix Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
Endologix Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Endologix Inc, Medical Equipment, Deal Details 12
Venture Financing 12
TriVascular Raises US$2 Million In Venture Financing 12
TriVascular Raises US$40 Million In Series E Financing 13
TV2 Raises US$0.07 Million In Venture Financing 15
Trivascular Raises Funds Through Initial Tranche Of Series D Financing 16
TriVascular Raises US$7.2 Million In Venture Financing 18
Partnerships 19
Endologix Enters into Co-Development Agreement with Japan Lifeline 19
Equity Offering 20
Endologix Plans to Raise Funds through Public Offering of Shares 20
Endologix Raises USD210 Million in Private Placement 21
Endologix Plans to Raise USD100 Million in Public Offering of Securities 22
Endologix Plans to Raise USD46.2 Million in Equity Offering of Shares 23
TriVascular Technologies Completes IPO For US$89.7 Million 24
Endologix Completes Public Offering Of Common Stock For US$40 Million 26
Debt Offering 27
Endologix Raises USD125 Million in Public Offering of 3.25% Notes Due 2020 27
TriVascular Raises USD10 Million in Private Placement 29
Endologix Completes Public Offering Of Notes Due 2018 For US$86.3 Million 30
Acquisition 32
Endologix Acquires TriVascular Technologies 32
Endologix Inc – Key Competitors 34
Endologix Inc – Key Employees 35
Endologix Inc – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Financial Announcements 37
Oct 02, 2018: Endologix Announces Third Quarter Preliminary Revenue Results and Raises Low End of 2018 Revenue Guidance Range 37
Aug 09, 2018: Endologix reports second quarter 2018 financial results 38
May 02, 2018: Endologix Announces First Quarter 2018 Financial Results 39
Feb 21, 2018: Endologix Reports Fourth Quarter and Fiscal Year 2017 Financial Results 40
Nov 07, 2017: Endologix Reports Third Quarter 2017 Financial Results 42
Aug 02, 2017: Endologix Reports Second Quarter 2017 Financial Results 43
May 04, 2017: Endologix Reports First Quarter 2017 Financial Results 44
Feb 22, 2017: Endologix Reports Results for the Fourth Quarter and Full Year 2016 45
Corporate Communications 47
Aug 15, 2018: Endologix appoints Jeffrey S. Brown as Chief Operations Officer 47
Jun 25, 2018: Endologix Names Jeffry Fecho As Chief Quality Officer 48
May 02, 2018: Endologix Names John Onopchenko As Chief Executive Officer 49
Feb 21, 2018: Endologix Announces Resignation Of John McDermott As Chief Executive Officer 50
Jan 29, 2018: Endologix Names Greg Morrow As Chief Marketing Officer 51
Jan 29, 2018: Endologix Appoints Greg Morrow as Chief Marketing Officer 52
Oct 19, 2017: Endologix Appoints John Onopchenko as Chief Operating Officer 53
Feb 06, 2017: Endologix Announces Appointment of Dan Lemaitre as Chairman of the Board 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
Endologix Inc, Medical Equipment, Key Facts, 2017 2
Endologix Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Endologix Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Endologix Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Endologix Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Endologix Inc, Deals By Market, 2012 to YTD 2018 9
Endologix Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
TriVascular Raises US$2 Million In Venture Financing 12
TriVascular Raises US$40 Million In Series E Financing 13
TV2 Raises US$0.07 Million In Venture Financing 15
Trivascular Raises Funds Through Initial Tranche Of Series D Financing 16
TriVascular Raises US$7.2 Million In Venture Financing 18
Endologix Enters into Co-Development Agreement with Japan Lifeline 19
Endologix Plans to Raise Funds through Public Offering of Shares 20
Endologix Raises USD210 Million in Private Placement 21
Endologix Plans to Raise USD100 Million in Public Offering of Securities 22
Endologix Plans to Raise USD46.2 Million in Equity Offering of Shares 23
TriVascular Technologies Completes IPO For US$89.7 Million 24
Endologix Completes Public Offering Of Common Stock For US$40 Million 26
Endologix Raises USD125 Million in Public Offering of 3.25% Notes Due 2020 27
TriVascular Raises USD10 Million in Private Placement 29
Endologix Completes Public Offering Of Notes Due 2018 For US$86.3 Million 30
Endologix Acquires TriVascular Technologies 32
Endologix Inc, Key Competitors 34
Endologix Inc, Key Employees 35
Endologix Inc, Subsidiaries 36

List of Figures
Endologix Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Endologix Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Endologix Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Endologix Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Endologix Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Endologix Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
Endologix Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Endologix Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

★海外企業調査レポート[Endologix Inc (ELGX):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Hawkins Inc (HWKN):企業の財務・戦略的SWOT分析
    Hawkins Inc (HWKN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Amdocs Limited:企業の戦略・SWOT・財務情報
    Amdocs Limited - Strategy, SWOT and Corporate Finance Report Summary Amdocs Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Compagnie Ivoirienne d’Electricite (CIEC):企業の財務・戦略的SWOT分析
    Summary Compagnie Ivoirienne d'Electricite (CIE), a subsidiary of Eranove, is a power company that provides power generation, transmission, and distribution services. The company offers exporting, importing and marketing of electricity. It provides operation and management of hydroelectric and therm …
  • Banco Santander-Chile:企業の戦略・SWOT・財務分析
    Banco Santander-Chile - Strategy, SWOT and Corporate Finance Report Summary Banco Santander-Chile - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Saizeriya Co., Ltd.:企業の戦略・SWOT・財務情報
    Saizeriya Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Saizeriya Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Karolinska Development AB (KDEV):製薬・医療:M&Aディール及び事業提携情報
    Summary Karolinska Development AB (Karolinska Development) is a life sciences investment company that develops innovations from science into commercial products. The company invests in start up's and growth of the pharmaceutical, medical device and biotechnology companies that develop specialty care …
  • Beth Israel Deaconess Medical Center Inc-医療機器分野:企業M&A・提携分析
    Summary Beth Israel Deaconess Medical Center Inc (BIDMC), a subsidiary of CareGroup Inc is a healthcare center that offers clinical care, biomedical research and education, health and wellness services. The center offers patient and family care services such as admitting, case management, ethics sup …
  • Mega Financial Holding Co., Ltd.:戦略・SWOT・企業財務分析
    Mega Financial Holding Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Mega Financial Holding Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • InvitroCue Ltd (IVQ):企業の財務・戦略的SWOT分析
    Summary InvitroCue Ltd (InvitroCue), formerly Bunuru Corporation Ltd, is a provider of bio-analytic solutions. The company provides digital pathology services such as digitization, sample preparation, staining, computer-aided diagnosis and consultation, telepathology, automated reporting and image a …
  • EV Energy Partners LP:企業のM&A・事業提携・投資動向
    EV Energy Partners LP - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's EV Energy Partners LP Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • RussNeft Oil Co (RNFT):石油・ガス:M&Aディール及び事業提携情報
    Summary RussNeft Oil Company (RussNeft) is an oil and gas company that produces, refines and distributes crude oil, gas and petroleum products. The company operates through its business divisions such as geologic exploration and reserves, production, marketing, research center, transport and gas pro …
  • Okklo Life Sciences BV:製薬・医療:M&Aディール及び事業提携情報
    Summary Okklo Life Sciences BV (Okklo) is a biopharmaceutical company that develops novel therapeutic solutions. The company offers cyclodextrin-based medicines for the treatment of neglected and orphan diseases. It also develops therapeutics for infectious diseases and lysosomal storage diseases. O …
  • CareDx Inc (CDNA):企業の製品パイプライン分析2018
    Summary CareDx Inc (CareDx), formerly XDx Inc, is a commercial stage molecular diagnostics company that develops, markets, and delivers diagnostic surveillance solutions. The company offers commercialized testing solution, the AlloMap heart transplant molecular test, is a noninvasive blood test used …
  • Special Metals Corp:企業の戦略・SWOT・財務分析
    Special Metals Corp - Strategy, SWOT and Corporate Finance Report Summary Special Metals Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Ion Beam Applications SA (IBAB):企業の財務・戦略的SWOT分析
    Ion Beam Applications SA (IBAB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • DBK Pharmaceutical:製薬・医療:M&Aディール及び事業提携情報
    Summary DBK Pharmaceutical (DBK Pharma) is a pharmaceutical company that develops, manufactures and markets pharmaceutical, herbal brands, food supplements, cosmetics and veterinary products. The company’s pharmaceutical products include chitocal capsule, debeskon, rentensar tablets, pressothioval, …
  • Yamana Gold Inc.:企業のM&A・事業提携・投資動向
    Yamana Gold Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Yamana Gold Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Armstrong Flooring Inc (AFI):企業の財務・戦略的SWOT分析
    Armstrong Flooring Inc (AFI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • SurModics Inc (SRDX):企業の財務・戦略的SWOT分析
    SurModics Inc (SRDX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Prime Capital AG-エネルギー分野:企業M&A・提携分析
    Summary Prime Capital AG (Prime Capital) is a financial service provider that offers asset management and professional services. The company provides infrastructure investments including renewable energy, private debt and hedge fund strategies through its independent asset management and advisory se …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆